SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

Pengfei Li; Yining Wang; Marla Lavrijsen; Mart M. Lamers; Annemarie C. de Vries; Robbert J. Rottier; Marco J. Bruno; Maikel P. Peppelenbosch; Bart L. Haagmans; Qiuwei Pan

doi:10.1038/s41422-022-00618-w

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

Pengfei Li
, Yining Wang
, Marla Lavrijsen
, Mart M. Lamers
, Annemarie C. de Vries
, Robbert J. Rottier
, Marco J. Bruno
, Maikel P. Peppelenbosch
, Bart L. Haagmans
, Qiuwei Pan^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

186 Citations (Scopus)

67 Downloads (Pure)

Original language	English
Pages (from-to)	322-324
Number of pages	3
Journal	Cell Research
Volume	32
Issue number	3
DOIs	https://doi.org/10.1038/s41422-022-00618-w
Publication status	Published - Mar 2022

Bibliographical note

Funding Information:
This work was supported by funding of a VIDI grant (91719300) from the Netherlands Organisation for Scientific Research and a Young Investigator Grant (10140) from the Dutch Cancer Society to Q.P., the ZonMw COVID project (114025011) to R.J.R., and a PhD fellowship from the China Scholarship Council to P.L. (201808370170).

Access to Document

10.1038/s41422-022-00618-wLicence: CC BY

s41422-022-00618-wFinal published version, 1.68 MBLicence: CC BY

Cite this

@article{2f950403600f43abb98d7c1d58c5655f,

title = "SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination",

author = "Pengfei Li and Yining Wang and Marla Lavrijsen and Lamers, \{Mart M.\} and \{de Vries\}, \{Annemarie C.\} and Rottier, \{Robbert J.\} and Bruno, \{Marco J.\} and Peppelenbosch, \{Maikel P.\} and Haagmans, \{Bart L.\} and Qiuwei Pan",

note = "Funding Information: This work was supported by funding of a VIDI grant (91719300) from the Netherlands Organisation for Scientific Research and a Young Investigator Grant (10140) from the Dutch Cancer Society to Q.P., the ZonMw COVID project (114025011) to R.J.R., and a PhD fellowship from the China Scholarship Council to P.L. (201808370170).",

year = "2022",

month = mar,

doi = "10.1038/s41422-022-00618-w",

language = "English",

volume = "32",

pages = "322--324",

journal = "Cell Research",

issn = "1001-0602",

publisher = "Springer Nature",

number = "3",

}

TY - JOUR

T1 - SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

AU - Li, Pengfei

AU - Wang, Yining

AU - Lavrijsen, Marla

AU - Lamers, Mart M.

AU - de Vries, Annemarie C.

AU - Rottier, Robbert J.

AU - Bruno, Marco J.

AU - Peppelenbosch, Maikel P.

AU - Haagmans, Bart L.

AU - Pan, Qiuwei

N1 - Funding Information: This work was supported by funding of a VIDI grant (91719300) from the Netherlands Organisation for Scientific Research and a Young Investigator Grant (10140) from the Dutch Cancer Society to Q.P., the ZonMw COVID project (114025011) to R.J.R., and a PhD fellowship from the China Scholarship Council to P.L. (201808370170).

PY - 2022/3

Y1 - 2022/3

UR - https://www.scopus.com/pages/publications/85123251630

U2 - 10.1038/s41422-022-00618-w

DO - 10.1038/s41422-022-00618-w

M3 - Comment/Letter to the editor

C2 - 35058606

AN - SCOPUS:85123251630

SN - 1001-0602

VL - 32

SP - 322

EP - 324

JO - Cell Research

JF - Cell Research

IS - 3

ER -

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

Bibliographical note

Access to Document

Other files and links

Cite this